{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:41:20Z","timestamp":1786977680559,"version":"build-2736575974"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":524,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>It is unclear whether activated partial thromboplastin time (aPTT) or anti-Xa is more accurate for monitoring heparin anticoagulation in mechanical circulatory support (MCS) patients. This study investigates the relationship between aPTT and anti-Xa in MCS patients and identifies predictors of discordance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>aPTT and anti-Xa were simultaneously measured in a prospective cohort of MCS patients receiving unfractionated heparin at a tertiary academic medical centre. Therapeutic aPTT and anti-Xa levels were 60\u2013100 s and 0.3\u20130.7 IU\/mL, respectively, and concordance was defined as both levels being subtherapeutic, therapeutic, or supratherapeutic. To identify predictors of discordance, both a machine learning random forest model and a multivariate regression model were applied to patient demographics, device type, and 14 laboratory variables; 23 001 pairs of simultaneously measured aPTT\/anti-Xa were collected from 699 MCS patients. aPTT and anti-Xa were concordant in 35.5% of paired observations and discordant in 64.5% (aPTT &amp;gt; antiXa 61.5%; aPTT &amp;lt; antiXa 3.0%). Discordance with a high aPTT relative to anti-Xa (aPTT &amp;gt; antiXa) was associated with high INR, eGFR, and total bilirubin, as well as low platelets, haemoglobin, pre-albumin, white blood cell count, and haptoglobin. Total artificial heart and durable ventricular assist devices were more likely to be associated with aPTT &amp;gt; anti-Xa than temporary MCS devices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>aPTT and anti-Xa were frequently discordant in MCS patients receiving heparin anticoagulation. Clinical conditions common in MCS patients such as concurrent warfarin use, malnutrition, haemolysis, and thrombocytopenia, as well as durable type of MCS devices were associated with a high aPTT relative to anti-Xa.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14816","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:39:25Z","timestamp":1715301565000},"page":"2742-2748","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Discordance Between aPTT and Anti-Xa in Monitoring Heparin Anticoagulation in Mechanical Circulatory Support"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0976-1386","authenticated-orcid":false,"given":"Song","family":"Li","sequence":"first","affiliation":[{"name":"Medical City Healthcare , Dallas, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Hematology & Oncology, Baylor College of Medicine , Houston, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Beckman","sequence":"additional","affiliation":[{"name":"University of Washington , Seattle, WA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Kim","sequence":"additional","affiliation":[{"name":"University of Washington , Seattle, WA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian A.","family":"Granich","sequence":"additional","affiliation":[{"name":"University of Washington , Seattle, WA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mondin","sequence":"additional","affiliation":[{"name":"Medical City Healthcare , Dallas, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Sabath","sequence":"additional","affiliation":[{"name":"University of Washington , Seattle, WA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Garcia","sequence":"additional","affiliation":[{"name":"University of Washington , Seattle, WA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudius","family":"Mahr","sequence":"additional","affiliation":[{"name":"Medical City Healthcare , Dallas, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"key":"2026012113144498700_ehf214816-bib-0001","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1016\/j.jacc.2017.04.031","article-title":"Left ventricular assist devices for lifelong support","volume":"69","author":"Pinney","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026012113144498700_ehf214816-bib-0002","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.116.004337","article-title":"Percutaneous mechanical circulatory support devices in cardiogenic shock","volume":"10","author":"Mandawat","year":"2017","journal-title":"Circ Cardiovasc Interv"},{"key":"2026012113144498700_ehf214816-bib-0003","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1001\/jamainternmed.2014.7856","article-title":"Trends in the use of percutaneous ventricular assist devices: analysis of national inpatient sample data, 2007 through 2012","volume":"175","author":"Khera","year":"2015","journal-title":"JAMA Intern Med"},{"key":"2026012113144498700_ehf214816-bib-0004","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.healun.2017.07.005","article-title":"Eighth annual INTERMACS report: special focus on framing the impact of adverse events","volume":"36","author":"Kirklin","year":"2017","journal-title":"J Heart Lung Transplant"},{"key":"2026012113144498700_ehf214816-bib-0005","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1124\/pr.115.011247","article-title":"Pharmacology of heparin and related drugs","volume":"68","author":"Mulloy","year":"2016","journal-title":"Pharmacol Rev"},{"key":"2026012113144498700_ehf214816-bib-0006","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1161\/hq0701.093686","article-title":"Mechanism of action and pharmacology of unfractionated heparin","volume":"21","author":"Hirsh","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026012113144498700_ehf214816-bib-0007","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1124\/pharmrev.122.000684","article-title":"Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin","volume":"32","author":"Vandiver","year":"2012","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"2026012113144498700_ehf214816-bib-0008","doi-asserted-by":"publisher","first-page":"171","DOI":"10.5045\/br.2016.51.3.171","article-title":"Establishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy","volume":"51","author":"Byun","year":"2016","journal-title":"Blood Res"},{"key":"2026012113144498700_ehf214816-bib-0009","doi-asserted-by":"publisher","first-page":"022","DOI":"10.1055\/s-0038-1677018","article-title":"How to optimize activated partial thromboplastin time (aPTT) testing: solutions to establishing and verifying normal reference intervals and assessing aPTT reagents for sensitivity to heparin, lupus anticoagulant, and clotting factors","volume":"45","author":"Favaloro","year":"2019","journal-title":"Semin Thromb Hemost"},{"key":"2026012113144498700_ehf214816-bib-0010","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/aor.13467","article-title":"Interference in the anti-Xa heparin activity assay due to hemolysis and icterus during pediatric extracorporeal life support","volume":"43","author":"Khan","year":"2019","journal-title":"Artif Organs"},{"key":"2026012113144498700_ehf214816-bib-0011","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.thromres.2017.07.006","article-title":"Should we abandon the aPTT for monitoring unfractionated heparin?","volume":"157","author":"Arachchillage","year":"2017","journal-title":"Thromb Res"},{"key":"2026012113144498700_ehf214816-bib-0012","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1345\/aph.1R635","article-title":"Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin","volume":"47","author":"Price","year":"2013","journal-title":"Ann Pharmacother"},{"key":"2026012113144498700_ehf214816-bib-0013","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/ajh.25565","article-title":"Clinical outcomes with unfractionated heparin monitored by anti-factor Xa vs. activated partial thromboplastin time","volume":"94","author":"Coons","year":"2019","journal-title":"Am J Hematol"},{"key":"2026012113144498700_ehf214816-bib-0014","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/MAT.0000000000001004","article-title":"Evaluation of anti-Xa and activated partial thromboplastin time monitoring of heparin in adult patients receiving extracorporeal membrane oxygenation support","volume":"66","author":"Arnouk","year":"2020","journal-title":"ASAIO J"},{"key":"2026012113144498700_ehf214816-bib-0015","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jchf.2014.11.009","article-title":"Anti\u2013factor Xa and activated partial thromboplastin time measurements for heparin monitoring in mechanical circulatory support","volume":"3","author":"Adatya","year":"2015","journal-title":"Jacc Hear Fail"},{"key":"2026012113144498700_ehf214816-bib-0016","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.thromres.2019.01.002","article-title":"Agreement between activated partial thromboplastin time and anti-Xa activity in critically ill patients receiving therapeutic unfractionated heparin","volume":"175","author":"Ratano","year":"2019","journal-title":"Thromb Res"},{"key":"2026012113144498700_ehf214816-bib-0017","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1177\/1076029617741363","article-title":"Performance of anti-factor Xa versus activated partial thromboplastin time for heparin monitoring using multiple nomograms","volume":"24","author":"Whitman-Purves","year":"2017","journal-title":"Clin Appl Thromb Hemost"},{"key":"2026012113144498700_ehf214816-bib-0018","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/bioinformatics\/btr597","article-title":"MissForest-non-parametric missing value imputation for mixed-type data","volume":"28","author":"Stekhoven","year":"2011","journal-title":"Bioinformatics"},{"key":"2026012113144498700_ehf214816-bib-0019","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.healun.2016.09.010","article-title":"Coagulation factor abnormalities related to discordance between anti-factor Xa and activated partial thromboplastin time in patients supported with continuous-flow left ventricular assist devices","volume":"35","author":"Adatya","year":"2016","journal-title":"J Hear Lung Transplant Official Publ Int Soc Hear Transplant"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/5\/2742\/64514838\/eschf_11_5_2742.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/5\/2742\/64514838\/eschf_11_5_2742.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:16:41Z","timestamp":1769019401000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/11\/5\/2742\/8271246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":19,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,9]]},"published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14816","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,5,9]]},"assertion":[{"value":"2024-01-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}